CN113121545B - Polycyclic macrocyclic lactam compound and preparation method and application thereof - Google Patents

Polycyclic macrocyclic lactam compound and preparation method and application thereof Download PDF

Info

Publication number
CN113121545B
CN113121545B CN202110450117.XA CN202110450117A CN113121545B CN 113121545 B CN113121545 B CN 113121545B CN 202110450117 A CN202110450117 A CN 202110450117A CN 113121545 B CN113121545 B CN 113121545B
Authority
CN
China
Prior art keywords
spe
sshg
cbma
fragment
nde
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110450117.XA
Other languages
Chinese (zh)
Other versions
CN113121545A (en
Inventor
李瑶瑶
高翔
颜雅倩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong University
Original Assignee
Shandong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong University filed Critical Shandong University
Priority to CN202110450117.XA priority Critical patent/CN113121545B/en
Publication of CN113121545A publication Critical patent/CN113121545A/en
Application granted granted Critical
Publication of CN113121545B publication Critical patent/CN113121545B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0012Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C12N9/0038Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12N9/0042NADPH-cytochrome P450 reductase (1.6.2.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93Ligases (6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y106/00Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/02Oxidoreductases acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12Y106/02004NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y603/00Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02Acid—amino-acid ligases (peptide synthases)(6.3.2)

Abstract

The invention relates to a polycyclic macrocyclic lactam compound and a preparation method and application thereof. The invention constructs engineering bacteria S001-cbm-OX4-sgr and S001-cbm-OX4-sshg _05717 for producing polycyclic macrocyclic lactam compounds. Realizes the preparation of the polycyclic macrocyclic lactam compound. The polycyclic macrocyclic lactam compound provided by the invention has stronger inhibitory activity on the secretion of virulence proteins of bacteria III type secretion systems, and has concentration gradient dependence, and the III type secretion systems widely exist in gram-negative pathogenic bacteria and have highly conservative structures, so the polycyclic macrocyclic lactam compound can be used for preparing medicaments for resisting the secretion of virulence proteins of the gram-negative pathogenic bacteria.

Description

Polycyclic macrocyclic lactam compound and preparation method and application thereof
Technical Field
The invention relates to a polycyclic macrocyclic lactam compound and a preparation method and application thereof, belonging to the technical field of natural pharmaceutical chemistry and microorganisms.
Background
The emergence of new drug-resistant bacteria and pathogenic bacteria continuously threatens the health and economic development of human beings, and the research and development of new active and new action mechanism antibiotics are imminent. Natural products are important resources for the development of new antibiotics, and polycyclic tetramic acid macrolactam (PoTeM) is a macrolactam compound with a tetramic acid structural unit and a polycyclic system. The structural diversity of PoTeMs is mainly reflected by the difference of polycyclic systems, such as 5/6/5 tricyclic, 5/5/6 tricyclic, 5/5 bicyclic and the like, and in addition, the structural diversity is further enriched by post-modification of hydroxylation, carbonylation, epoxidation and the like catalyzed by cytochrome P450 enzymes. The PoTeMs have various biological activities of resisting bacteria, fungi, protozoans, ulcers and tumors, inhibiting the secretion of virulence proteins of a III-type secretion system and the like.
The action mechanism of the traditional antibiotics is mainly bacteriostasis or sterilization, while the action mechanism of inhibiting the secretion of virulence protein of a III-type secretion system of gram-negative pathogenic bacteria is mainly to make the pathogenic bacteria lose virulence, pathogenic capability and survival competitive capability by targeting the virulence protein, so that the antibiotic is a novel action mechanism against pathogenic bacteria. The PoTeMs gradually form a new antibiotic family with complex structures, rich biological activity and unique action mechanisms, and have potential medicinal value.
Chinese patent document CN106008531A discloses pancreatic cancer resistance application of polycyclic condensed macrocyclic lactam compounds. Chinese patent document CN108623607A discloses a 5,5,6-polycyclic tetramic acid-containing macrocyclic lactam compound, and a preparation method and application thereof. However, the compounds provided in these two patents are functional as antitumor and antifungal and are not related to antibacterial aspects.
A published article, "polycyclic tetramic acid macrocyclic lactam produced by Streptomyces S001 metabolism", has been reported to be the unexpected activation of the host' S own PoTeMs gene cluster mtm (GenBank No. MN817126) upon expression of recombinant plasmids in heterologous hosts, resulting in the reported compound montamide A, which has weak cytotoxic activity but no reported activity of inhibiting the secretion of bacterial virulence proteins.
At present, only one literature report about PoTeMs compounds with antibacterial toxicity and the preparation of the compounds is that Targeted discovery and combinatorial biosynthesis of multicyclic tetramate maize combamides A-E, although the combamides biosynthesis gene cluster cbm (GenBank No. MH167394) is modified and expressed heterologously by using a combination biosynthesis means, the cytochrome P450 enzyme gene contained in the engineering bacteria constructed in the paper is cbmD.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a polycyclic macrocyclic lactam compound and a preparation method and application thereof.
The technical scheme of the invention is as follows:
the structural formula of the polycyclic macrocyclic lactam compound is shown as the formula (I) or (II):
Figure BDA0003038343090000021
the engineering bacteria for producing the polycyclic macrocyclic lactam compound are characterized in that the metabolite of the engineering bacteria contains the polycyclic macrocyclic lactam compound shown as the formula (I) or (II).
According to the invention, the engineering bacteria preferably contain a polyketide-non-ribosomal peptide synthase gene cbmA responsible for synthesis of PoTeMs polyene skeletons, and the nucleotide sequence is shown as SEQ ID NO. 1; the flavin-dependent oxidoreductase gene cbmB responsible for the synthesis of the middle five-membered ring of the polycyclic system has a nucleotide sequence shown in SEQ ID No. 2; the flavin-dependent oxidoreductase gene cbmC responsible for five-membered ring synthesis outside the polycyclic system has a nucleotide sequence shown in SEQ ID No. 3; the NADPH-dependent oxidoreductase gene OX4 responsible for synthesis of six-membered rings inside the polycyclic system has a nucleotide sequence shown in SEQ ID No. 4; the cytochrome P450 enzyme gene sgr810 or the cytochrome P450 enzyme gene sshg _05717 which is responsible for the post-oxidation modification has the nucleotide sequences shown as SEQ ID NO.5 and SEQ ID NO.6 respectively.
The construction method of the engineering bacteria for producing the polycyclic macrocyclic lactam compound comprises the following steps:
(1) Carrying out PCR amplification by taking the genomic DNA of Streptomyces sp.S10 as a template to obtain flavin-dependent oxidoreductase gene cbmB and flavin-dependent oxidoreductase gene cbmC gene segments with NdeI and SpeI enzyme cutting sites respectively introduced at two ends of the sequence; carrying out PCR amplification by using the genome DNA of Lysobacter enzymogenes C3 as a template to obtain NADPH dependent oxidoreductase OX4 gene segments with NdeI and SpeI enzyme cutting sites respectively introduced into two ends of the sequence; performing PCR amplification by taking Streptomyces albus J1074 genome DNA as a template to obtain a cytochrome P450 enzyme gene sshg _05717 gene segment with NdeI and SpeI enzyme cutting sites respectively introduced to two ends of the sequence; the four PCR products are subjected to double enzyme digestion by NdeI and SpeI to obtain cbmB-NdeI/SpeI, cbmC-NdeI/SpeI, OX4-NdeI/SpeI and sshg _05717-NdeI/SpeI fragments; artificially synthesizing a cytochrome P450 enzyme gene sgr810, cloning the cytochrome P450 enzyme gene sgr into a vector fragment pMV-AMP to obtain a plasmid pMV-sgr, and performing double enzyme digestion on the plasmid by NdeI and SpeI to obtain a sgr-NdeI/SpeI fragment; cbmB-NdeI/SpeI, cbmC-NdeI/SpeI, OX4-NdeI/SpeI, sgr810-NdeI/SpeI and sshg _05717-NdeI/SpeI are respectively connected with vector fragments pUC-kasOp/ermEp-NdeI/SpeI through ligase, the connection products are respectively transformed into escherichia coli DH5 alpha competent cells, and plasmids pUC-cbmB, pUC-cbmC, pUC-OX4, pUC-sgr810 and pUC-sshg _05717 are obtained after verification and extraction;
(2) Carrying out double enzyme digestion on plasmids pUC-cbmB and pUC-OX4 by MfeI and SpeI respectively to obtain cbmB-MfeI/SpeI and OX4-MfeI/SpeI fragments; plasmids pUC-cbmC, pUC-sgr and pUC-sshg _05717 are subjected to double enzyme digestion by XbaI and PstI respectively to obtain fragments cbmC-XbaI/PstI, sgr810-XbaI/PstI and sshg _ 05717-XbaI/PstI; the cbmB-MfeI/SpeI, the cbmC-XbaI/PstI and the vector fragment pSET5035-MfeI/PstI are connected by ligase to obtain a plasmid pSET5035-cbmB-C; OX4-MfeI/SpeI, sgr810-XbaI/PstI and the vector fragment pSET5035-MfeI/PstI are connected by ligase to obtain a plasmid pSET5035-OX4-sgr810; OX4-MfeI/SpeI, sshg _05717-XbaI/PstI and the vector fragment pSET5035-MfeI/PstI are connected by ligase to obtain a plasmid pSET5035-OX4-sshg _05717;
(3) Carrying out double enzyme digestion on plasmid pUC-cbmA by MfeI and SpeI to obtain cbmA-MfeI/SpeI; the plasmid pSET5035-cbmB-C is subjected to double digestion by XbaI and PstI to obtain a cbmB-C-XbaI/PstI fragment; the cbmA-MfeI/SpeI, the cbmB-C-XbaI/PstI and the vector fragment pSET5035-MfeI/PstI are connected by a ligase to obtain a plasmid pSET5035-cbmA-B-C;
(4) Plasmid pSET5035-cbmA-B-C is subjected to MfeI and SpeI double enzyme digestion to obtain a cbmA-B-C-MfeI/SpeI fragment; plasmids pSET5035-OX4-sgr and pSET5035-OX4-sshg _05717 are subjected to double enzyme digestion by XbaI and PstI respectively to obtain OX 4-sgr-XbaI/PstI and OX4-sshg _05717-XbaI/PstI fragments; the cbmA-B-C-MfeI/SpeI, OX 4-sgr-XbaI/PstI and the carrier fragment pSET5035-MfeI/PstI are connected by a ligase to obtain an expression carrier pSET5035-cbm-OX 4-3262 zxft 32810; the cbmA-B-C-MfeI/SpeI, OX4-sshg _05717-XbaI/PstI and the vector fragment pSET5035-MfeI/PstI are connected by ligase to obtain an expression vector pSET5035-cbm-OX4-sshg _05717;
(5) Respectively electrically transforming the expression vectors pSET5035-cbm-OX4-sgr and pSET5035-cbm-OX4-sshg _05717 obtained in the step (4) into escherichia coli S17-1 competent cells, transferring the expression vectors into Streptomyces sp.S001 through escherichia coli S17-1 donor bacteria, and obtaining the engineering bacteria S001-cbm-OX4-sgr and S001-cbm-OX4-sshg _05717 for producing the polycyclic macrocyclic lactam compound after zygote purification and PCR verification.
Preferably, in step (1), the PCR amplification primer sequences are as follows:
NdeI-cbmB-F:5’-cggacatatgcggcgtagtaacagggtg-3’
SpeI-cbmB-R:5’-attactagttcacctcatgctcttgtcg-3’
NdeI-cbmC-F:5’-cggacatatgcctcgcaagccccg-3’
SpeI-cbmC-R:5’-attactagttcagcggacgtgaacgg-3’
NdeI-OX4-F:5’-aggcggacatatgaagaccgaacgttgggtgg-3’
SpeI-OX4-R:5’-attactagttcacacccgcaccagcacct-3’
NdeI-sshg_05717-F:5’-cggacatatgtccgccgcaacacccgcc-3’
SpeI-sshg_05717-R:5’-attactagtcaccaggtgaccgggagcc-3’
PCR amplification conditions: pre-denaturation at 95 deg.C for 5min; denaturation at 95 ℃ for 30sec, annealing at 65 ℃ for 30sec, elongation at 72 ℃ for 2min, and 30 cycles; final extension, 5min at 72 ℃.
In the invention, the vector fragment pUC-kasOp/ermEp-NdeI/SpeI is obtained by double digestion of plasmid pUC-kasOp/ermEp with NdeI and SpeI; the vector fragment pSET5035-MfeI/PstI is obtained by carrying out MfeI/PstI double digestion on the plasmid pSET 5035-KT.
The invention artificially synthesizes cytochrome P450 enzyme gene sgr810 according to the prior art, and a vector fragment pMV-AMP is the prior plasmid vector.
Preferably, in step (3), the plasmid pUC-cbmA is prepared as follows:
carrying out PCR amplification by using fosmid XIV-12H containing polyketide-non-ribosomal peptide synthase gene cbmA as a template to obtain partial cbmA fragments with NdeI and SpeI enzyme cutting sites respectively introduced into two ends of a sequence; carrying out double enzyme digestion on the obtained PCR product by NdeI and SpeI to obtain a cbmA-part1-NdeI/SpeI fragment, connecting the cbmA-part1-NdeI/SpeI fragment with a vector fragment pUC-ermEp-NdeI/SpeI by using a ligase, transforming a connecting product into an Escherichia coli DH5 alpha competent cell, verifying and extracting to obtain a plasmid pUC-cbmA-part1, and carrying out double enzyme digestion on the plasmid by PstI and SphI to obtain a cbmA-part1-PstI/SphI fragment; carrying out double enzyme digestion on Fosmid XIV-12H by PstI and SphI to obtain a cbmA-part2-PstI/SphI fragment, connecting the cbmA-part1-PstI/SphI fragment and the cbmA-part2-PstI/SphI fragment by ligase, converting a connecting product into escherichia coli DH5 alpha competent cells respectively, and obtaining a plasmid pUC-cbmA after verification and extraction;
wherein, the PCR amplification primer sequence is as follows:
NdeI-cbmA-LF:5’-cggacatatgtcggacctatgcaaggtc-3’
SpeI-cbmA-LR:5’-attactagtctacgccgcatgcgagattgatgtggggtggga-3’
PCR amplification conditions: pre-denaturation at 95 deg.C for 5min; denaturation at 95 ℃ for 30sec, annealing at 65 ℃ for 30sec, elongation at 72 ℃ for 2min, and 30 cycles; final extension, 5min at 72 ℃.
The preparation method of the polycyclic macrocyclic lactam compound comprises the following steps:
(1) Respectively inoculating the engineering bacteria S001-cbm-OX4-sgr810 and S001-cbm-OX4-sshg _05717 on a YMG solid agar culture medium, and carrying out amplification culture at 25-35 ℃ for 8-15 days;
(2) Cutting a YMG solid agar culture medium and engineering bacteria S001-cbm-OX4-sgr thallus into blocks, soaking and extracting for 2-4 times by using an extracting solution ethyl acetate-methanol-glacial acetic acid (80, 15, v/v/v);
(3) Cutting a YMG solid agar culture medium and engineering bacteria S001-cbm-OX4-sshg _05717 into blocks, soaking and extracting an extracting solution ethyl acetate-methanol-glacial acetic acid (80, 15, v/v/v) overnight for 2-4 times, then combining leaching solutions, respectively combining a water phase and an organic phase of the leaching solutions, concentrating under reduced pressure to 200-400 mL, then respectively extracting with ethyl acetate of the same volume for 2-4 times, combining extracted ethyl acetate phases, concentrating under reduced pressure to dryness, and obtaining an ethyl acetate extract B;
(4) Extracting the ethyl acetate extract A with petroleum ether and methanol in equal volume to obtain a methanol phase and a petroleum ether phase, and washing a light yellow precipitate separated from the methanol phase with methanol for 2-4 times to obtain the polycyclic macrocyclic lactam compound shown in the formula (I); and extracting the ethyl acetate extract B by using petroleum ether and methanol with equal volume to obtain a methanol phase and a petroleum ether phase, washing a light yellow precipitate separated from the methanol phase for 2-4 times by using methanol-dichloromethane (2, 1, v/v), and separating by using a sephadex column chromatography to obtain a component B1, wherein the component B1 is prepared by using HPLC to obtain the polycyclic macrocyclic lactam compound shown in the formula (II).
According to the invention, in the step (1), the expansion culture is 8-10L, and the culture conditions are 30 ℃ and 12d.
Preferably, in step (1), the formula of the YMG solid agar medium is: yeast extract 4g, malt extract 10g, glucose 4g,10M NaOH pH value to 7.2-7.4, pure water constant volume to 1L,2% agar, 115 deg.C high pressure sterilization for 30min.
The polycyclic macrocyclic lactam compound is applied to the preparation of medicaments for resisting gram-negative bacteria virulence protein secretion.
An anti-gram-negative bacterial virulence protein secretion medicament comprising a polycyclic macrocyclic lactam compound of the invention and one or more pharmaceutically acceptable carriers or excipients.
Advantageous effects
1. The polycyclic macrocyclic lactam compound provided by the invention has stronger inhibitory activity on the secretion of virulence protein of bacteria III type secretion system, and has concentration gradient dependence, and the III type secretion system widely exists in gram-negative pathogenic bacteria and has highly conservative structure, so the polycyclic macrocyclic lactam compound can be used for preparing medicaments for resisting the secretion of virulence protein of gram-negative pathogenic bacteria.
2. The invention constructs a polypeptide isolated macrocyclic compound which comprises a polyketone-nonribosomal peptide synthase gene cbmA responsible for PoTeMs polyene skeleton synthesis, a flavin-dependent oxidoreductase gene cbmB responsible for five-membered ring synthesis in a polycyclic system, a flavin-dependent oxidoreductase gene cbmC responsible for five-membered ring synthesis outside the polycyclic system, an NADPH-dependent oxidoreductase gene OX4 responsible for six-membered ring synthesis inside the polycyclic system, a cytochrome P450 gene sgr responsible for post-oxidation modification or an expression vector pSET5035-cbm-OX4-sgr and pSET5035-cbm-OX4-sshg _05717, realizes the heterologous expression of a combamides core skeleton gene, an OX4 gene and different cytochrome P450 enzyme genes in Streptomyces sp.S001, and further obtains a macrocyclic isolated macrocyclic compound from engineering bacteria S001-cbm-4-sgr and S001-cbm-ssox 717 and purified macrocyclic isolated macrocyclic compounds in Streptomyces sp.S001. The invention utilizes a combined biosynthesis means to obtain the 'non-natural' PoTeM compound by modifying and heterologously expressing the combamides biosynthetic gene cluster cbm.
Drawings
FIG. 1 is a schematic diagram of the construction process of the engineering bacteria for producing the polycyclic macrocyclic lactam compound.
FIG. 2 is a gene PCR amplification agarose gel electrophoresis diagram of the engineering bacteria for producing polycyclic macrocyclic lactam compounds according to the invention;
in the figure: band 1 is a cbmB gene fragment; band 2 is cbmC gene fragment; band 3 is an OX4 gene fragment; lane 4 is sshg _05717 gene fragment.
FIG. 3 shows PCR-verified agarose gel electrophoresis of engineering bacteria for producing polycyclic macrocyclic lactams.
FIG. 4 is a HPLC check chart of metabolites of engineered bacteria of the present invention for the production of polycyclic macrocyclic lactams.
FIG. 5 is a graph of the effect of polycyclic macrocyclic lactams on Salmonella growth in accordance with the present invention.
FIG. 6 shows the inhibitory activity of polycyclic macrocyclic lactam compounds of the present invention against the secretion of virulence proteins of the Salmonella type III secretion system in vitro.
Detailed Description
The invention is further described below with reference to the following figures and examples.
Example 1 construction of plasmid pUC-cbmA
Carrying out PCR amplification on a cbmA-part1 fragment by using fosmid XIV-12H containing a polyketide-non-ribosomal peptide synthase gene cbmA as a template, designing primers by using bioinformatics software, and respectively introducing NdeI and SpeI single enzyme cutting sites at two ends of the sequence, wherein the sequences of the primers are as follows:
NdeI-cbmA-LF:5’-cggacatatgtcggacctatgcaaggtc-3’
SpeI-cbmA-LR:5’-attactagtctacgccgcatgcgagattgatgtggggtggga-3’
preparing a PCR amplification system according to the kit instruction;
PCR amplification conditions: pre-denaturation at 95 deg.C for 5min; denaturation at 95 ℃ for 30sec, annealing at 65 ℃ for 30sec, elongation at 72 ℃ for 2min, and 30 cycles; final extension, 5min at 72 ℃.
The obtained PCR product is recovered by a gel recovery kit, the PCR product and the vector plasmid pUC-kasOp/ermEp are respectively subjected to double enzyme digestion by NdeI and SpeI, the cbmA-part1-NdeI/SpeI fragment obtained by enzyme digestion and the vector fragment pUC-ermEp-NdeI/SpeI are connected by ligase, the connection product is introduced into escherichia coli DH5 alpha competent cells by a chemical transformation method, the competent cells are coated on LB solid agar plate containing 50 mu g/mL kanamycin and are cultured overnight at 37 ℃, positive recombinants are picked, and the plasmid pUC-cbmA-part1 is extracted from the positive recombinants by a plasmid extraction kit. The plasmid pUC-cbmA-part1 is subjected to double digestion by PstI and SphI to obtain a cbmA-part1-PstI/SphI fragment. The plasmid pUC-cbmA is extracted from positive recombinants by a plasmid extraction kit after the positive recombinants are picked up by introducing a positive recombinants into a plasmid pUC-cbmA-part 2-PstI/SphI fragment obtained by double enzyme digestion of PstI and SphI of Fosmid XIV-12H, connecting the cbmA-part1-PstI/SphI fragment with the cbmA-part2-PstI/SphI fragment through ligase, introducing a connecting product into an Escherichia coli DH5 alpha competent cell through a chemical transformation method, coating the competent cell on an LB solid agar plate containing 50 mu g/mL kanamycin, culturing overnight at 37 ℃.
Example 2 construction of plasmids pUC-cbmB, pUC-cbmC, pUC-OX4, pUC-sgr and pUC-sshg _05717
S10 genomic DNA of Streptomyces sp.S10 is taken as a template to carry out PCR amplification on a cbmB fragment, bioinformatics software is utilized to design primers, ndeI and SpeI single enzyme cutting sites are respectively introduced into two ends of the sequence, and the sequences of the primers are as follows:
NdeI-cbmB-F:5’-cggacatatgcggcgtagtaacagggtg-3’
SpeI-cbmB-R:5’-attactagttcacctcatgctcttgtcg-3’
s10 genome DNA of Streptomyces sp.S10 is taken as a template to carry out PCR amplification on a cbmC fragment, bioinformatics software is utilized to design primers, ndeI and SpeI single enzyme cutting sites are respectively introduced into two ends of a sequence, and the sequences of the primers are as follows:
NdeI-cbmC-F:5’-cggacatatgcctcgcaagccccg-3’
SpeI-cbmC-R:5’-attactagttcagcggacgtgaacgg-3’
carrying out PCR amplification on OX4 fragments by taking genome DNA of Lysobacter enzymogenes C3 as a template, designing primers by using bioinformatics software, and respectively introducing NdeI and SpeI single enzyme cutting sites at two ends of the sequence, wherein the sequences of the primers are as follows:
NdeI-OX4-F:5’-aggcggacatatgaagaccgaacgttgggtgg-3’
SpeI-OX4-R:5’-attactagttcacacccgcaccagcacct-3’
PCR amplification is carried out on sshg _05717 fragments by taking Streptomyces albus J1074 genome DNA as a template, primers are designed by bioinformatics software, ndeI and SpeI single enzyme cutting sites are respectively introduced at two ends of the sequence, and the sequences of the primers are as follows:
NdeI-sshg_05717-F:5’-cggacatatgtccgccgcaacacccgcc-3’
SpeI-sshg_05717-R:5’-attactagtcaccaggtgaccgggagcc-3’
preparing a PCR amplification system according to the kit instruction;
PCR amplification conditions: pre-denaturation at 95 deg.C for 5min; denaturation at 95 ℃ for 30sec, annealing at 65 ℃ for 30sec, elongation at 72 ℃ for 2min, and 30 cycles; final extension, 5min at 72 ℃.
The obtained PCR product is analyzed and detected by 0.8% agarose gel electrophoresis, as shown in figure 2, an electrophoresis band 1 with the size of 1681bp is a cbmB gene fragment, an electrophoresis band 2 with the size of 1750bp is a cbmC gene fragment, an electrophoresis band 3 with the size of 1075bp is an OX4 gene fragment, an electrophoresis band 4 with the size of 1215bp is a sshg _05717 gene fragment, and the above target fragments are recovered by a gel recovery kit.
Artificially synthesizing cytochrome P450 enzyme gene sgr810 according to the prior art, and then cloning the cytochrome P450 enzyme gene sgr gene into a vector fragment pMV-AMP to obtain a plasmid pMV-sgr810; PCR fragments of cbmB, cbmC, OX4 and sshg _05717, plasmid pMV-3252 zxft 32810 containing artificially synthesized cytochrome P450 enzyme gene sgr and vector plasmid pUC-kasOp/ermEp were double-digested with NdeI and SpeI, respectively, and the resulting cbmB-NdeI/SpeI, cbmC-NdeI/SpeI, OX4-NdeI/SpeI, sshg _05717-NdeI/SpeI and sgr-NdeI/SpeI were ligated with vector fragments pUC-kasOp/ermEp, respectively, by a ligase, and the ligation products were chemically transformed into E.coli 5 α competent cells, spread on pUC-pUC 50 μ g/kanamycin-containing solid pUC positive plates, cultured at 37 ℃, and extracted from recombinant plasmids containing sbc-05717 and sshOX 25 by overnight using a recombinant DNA-34zmgo-plasmid-34mC-05717 and a plasmid-34mOX-3425-34mCe-plasmid.
Example 3: construction of expression vectors pSET5035-cbm-OX4-sgr810 and pSET5035-cbm-OX4-sshg _05717
Plasmids pUC-cbmA, pUC-cbmB, pUC-OX4 and vector plasmid pSET5035-KT are subjected to double enzyme digestion by MfeI and SpeI to obtain cbmA-MfeI/SpeI, cbmB-MfeI/SpeI, OX4-MfeI/SpeI fragments and vector fragment pSET5035-MfeI/PstI.
Plasmids pUC-cbmC, pUC-sgr and pUC-sshg _05717 are subjected to double digestion with XbaI and PstI respectively to obtain cbmC-XbaI/PstI, sgr810-XbaI/PstI and sshg _05717-XbaI/PstI fragments.
The cbmB-MfeI/SpeI, cbmC-XbaI/PstI and the vector fragment pSET5035-MfeI/PstI are connected by a ligase to obtain a plasmid pSET5035-cbmB-C.
The plasmid pSET5035-cbmB-C is subjected to double digestion by XbaI and PstI to obtain a cbmB-C-XbaI/PstI fragment; the cbmA-MfeI/SpeI, cbmB-C-XbaI/PstI and the vector fragment pSET5035-MfeI/PstI are connected by ligase to obtain a plasmid pSET5035-cbmA-B-C.
OX4-MfeI/SpeI, sgr810-XbaI/PstI and the vector plasmid pSET5035-MfeI/PstI are connected by ligase to obtain a plasmid pSET5035-OX4-sgr810.
OX4-MfeI/SpeI, sshg _05717-XbaI/PstI and the vector plasmid pSET5035-MfeI/PstI are connected by ligase to obtain a plasmid pSET5035-OX4-sshg _05717.
After plasmid pSET5035-cbmA-B-C is subjected to double enzyme digestion by MfeI and SpeI, a cbmA-B-C-MfeI/SpeI fragment is obtained.
Plasmids pSET5035-OX4-sgr and pSET5035-OX4-sshg _05717 are subjected to double digestion by XbaI and PstI respectively to obtain OX 4-sgr-XbaI/PstI and OX4-sshg _05717-XbaI/PstI fragments.
The cbmA-B-C-MfeI/SpeI, OX 4-sgr-XbaI/PstI and the vector plasmid pSET5035-MfeI/PstI are connected by ligase to obtain an expression vector pSET5035-cbm-OX 4-3262 zxft 32810.
The cbmA-B-C-MfeI/SpeI, OX4-sshg _05717-XbaI/PstI and the vector plasmid pSET5035-MfeI/PstI are connected by ligase to obtain an expression vector pSET5035-cbm-OX4-sshg _05717.
Example 4: construction of engineering bacteria S001-cbm-OX4-sgr810 and S001-cbm-OX4-sshg _05717
Respectively electrotransforming the expression vectors pSET5035-cbm-OX4-sgr and pSET5035-cbm-OX4-sshg _05717 into competent cells of Escherichia coli S17-1, respectively, transferring the heterologous expression vectors pSET5035-cbm-OX4-sgr and pSET5035-cbm-OX4-sshg _05717 into Streptomyces sp.001 competent cells via the Escherichia coli S17-1, plating on SFM solid agar medium, culturing at 30 ℃ for 15 hours in an inverted manner, covering each of the conjugal plates with 1mg of nalidixic acid and 1mg of arabinoside antibiotic, picking up the conjugar at 30 ℃ for about 5 days and inoculating to YMG solid agar medium containing 25. Mu.g/mL of nalidixic acid and 30. Mu.g/mL of arabinoside antibiotics, purifying, culturing at 30 ℃ for about 5 days, picking up the pure conjugar in YMG solid agar medium containing 25. Mu.g/mL of nalidixic acid and 30. Mu.g/mL of arabinoside antibiotics, and extracting DNA from the genome in an inverted culture medium containing 30. Mu.g/mL of conjugar-L of arabinoside antibiotics, culturing at 37 ℃ for about 220, and extracting DNA at 37 rpm. Design and adopt primer InS10PKSNRPS-verF/InS10-verR to carry out PCR verification to the genomic DNA of the zygote, PCR verification agarose gel electrophoresis is shown in figure 3, the expected size of the PCR product of the engineering bacteria S001-cbm-OX4-sgr810 is 6629bp, and the expected size of the PCR product of the engineering bacteria S001-cbm-OX4-sshg _05717 is 6621bp. The spliceosomes with the expected sizes of the PCR products are engineering bacteria S001-cbm-OX4-sgr810 and S001-cbm-OX4-sshg _05717 for producing the polycyclic macrocyclic lactam compound.
The SFM solid agar culture medium comprises the following components: 20g of soybean cake powder (boiled with soft fire for half an hour, filtered by 4 layers of gauze), 20g of mannitol, adding pure water to a constant volume of 1L, adjusting the pH value to 7.2-7.4,2% agar, and autoclaving at 121 ℃ for 30min.
The formula of the YMG solid agar culture medium is as follows: yeast extract 4g, malt extract 10g, glucose 4g,10M NaOH to adjust pH to 7.2-7.4, pure water to volume of 1L,2% agar, and autoclaving at 115 deg.C for 30min. The extraction of pure zygotic DNA was performed according to the prior art, and the PCR verified primer sequences were as follows:
InS10PKSNRPS-verF:5’-ccagggactacatcgccttctgc-3’
InS10-verR:5’-gctcactcaaaggcggtaatacgg-3’
PCR conditions were as follows: pre-denaturation at 95 deg.C for 5min; denaturation at 95 ℃ for 30sec, annealing at 61 ℃ for 30sec, elongation at 72 ℃ for 1min, and 30 cycles; final extension, 5min at 72 ℃.
Example 5: fermentation culture of engineering bacteria for producing polycyclic macrocyclic lactam compound
The engineering bacteria S001-cbm-OX4-sgr and S001-cbm-OX4-sshg _05717 prepared in example 4 were respectively inoculated in YMG solid agar medium, cultured for 10 days at 30 ℃ for 10L enlargement, the medium together with the mycelia cut pieces were soaked and extracted once in an extraction solution of ethyl acetate-methanol-glacial acetic acid (80, 5, v/v/v) overnight, the extraction solution was concentrated under reduced pressure at 25 ℃ until dried to obtain a crude extract, and then the crude extract was treated with CH 3 OH is dissolved, and the supernatant is taken for HPLC detection.
The formula of the YMG solid agar culture medium is as follows: yeast extract 4g, malt extract 10g, glucose 4g,10M NaOH to adjust pH to 7.2-7.4, pure water to volume of 1L,2% agar, and autoclaving at 115 deg.C for 30min.
As shown in FIG. 4, the HPLC assay of this example shows that both of the engineered bacteria S001-cbm-OX4-sgr and S001-cbm-OX4-sshg _05717 can produce two compounds, referred to as compound 1 and compound 2, respectively, but the engineered bacteria S001-cbm-OX4-sgr produces compound 1 at a higher yield and the engineered bacteria S001-cbm-OX4-sshg _05717 produces compound 2 at a higher yield, as shown in FIG. 4.
Example 6: preparation of Compounds 1 and 2
The preparation method of the polycyclic macrocyclic lactam compound comprises the following steps:
(1) Inoculating the engineering bacteria S001-cbm-OX4-sgr810 to a YMG solid agar culture medium, and performing inverted culture at 30 ℃ for 12 days; inoculating the engineering bacteria S001-cbm-OX4-sshg _05717 to a YMG solid agar culture medium, and performing inverted culture at 30 ℃ for 12 days;
(2) Cutting YMG solid agar culture medium and engineering bacteria S001-cbm-OX4-sgr into small blocks, soaking and extracting overnight in ethyl acetate-methanol-glacial acetic acid (80, 15, v/v/v) of an extracting solution for 3 times, combining leaching solutions, concentrating the leaching solution at 25 ℃ under reduced pressure to 300mL, extracting with ethyl acetate of the same volume for 3 times, combining extracted ethyl acetate phases, and concentrating under reduced pressure to dryness to obtain an ethyl acetate extract A;
(3) Cutting YMG solid agar culture medium and engineering bacteria S001-cbm-OX4-sshg _05717 into small blocks, soaking and extracting in ethyl acetate-methanol-glacial acetic acid (80, 15, v/v/v) overnight for 3 times, mixing leaching solutions, mixing the water phase and the organic phase of the leaching solution, concentrating under reduced pressure at 25 ℃ to 300mL, extracting with ethyl acetate of the same volume for 3 times, mixing the extracted ethyl acetate phases, and concentrating under reduced pressure at 25 ℃ to dryness to obtain ethyl acetate extract B;
(4) Extracting the ethyl acetate extract A with petroleum ether and methanol of the same volume to obtain a methanol phase and a petroleum ether phase, and washing a light yellow precipitate separated from the methanol phase with methanol for 3 times to obtain a compound 1; the ethyl acetate extract B was extracted with petroleum ether and methanol of equal volume to obtain a methanol phase and a petroleum ether phase, and the light yellow precipitate precipitated from the methanol phase was washed 3 times with methanol-dichloromethane (2, 1, v/v) and then subjected to Sephadex column chromatography (Sephadex LH-20,60g, methanol-dichloromethane, 10s/d,3 mL/tube) to give fraction B1, and subjecting B1 to semi-preparative HPLC (90% CH) 3 CN,4mL/min, UV 320 nm) to give Compound 2.
Example 7: structural characterization of Compound 1 and Compound 2
The compound 1 and the compound 2 prepared in example 6 were subjected to spectroscopic data analysis by 1D and 2D NMR, UV, IR and HRMS, and the analysis results are shown in table 1.
TABLE 1 preparation of Compound 1 and Compound 2 1 H and 13 C NMR(Pyridine-d 5 ) Data of
Figure BDA0003038343090000101
Figure BDA0003038343090000111
]25+126.17(c 1.00,CH 3 OH-CH 2 Cl 2 1:1,v/v);UV-vis(CH 3 CN)λ max :232,321nm;IR:3319, ]25+167.56(c 1.00,CH 3 OH-CH 2 Cl 2 1:1,v/v);UV-vis(CH 3 CN)λ max :215,323nm;IR:3332, 1691,1656,1360cm -1
As shown in Table 1, the molecular formula of Compound 1 is C as determined by high resolution Mass Spectrometry (HR-ESIMS) 29 H 40 O 5 N 2 (m/z 497.3011 [M+H] + ,calcd.for C 29 H 41 O 5 N 2 + ,497.3015). The molecular formula of the compound 2 is C measured by high resolution mass spectrum (HR-ESIMS) 29 H 40 O 4 N 2 (m/z 481.3067[M+H] + ,calcd.for C 29 H 41 O 4 N 2 + ,481.3066). Determining that the compound 1 and the compound 2 are both polycyclic macrocyclic lactam compounds, and the specific structural formula is shown as the following formula:
Figure BDA0003038343090000112
example 8: testing the Effect of Compound 1 and Compound 2 on the growth of Salmonella typhimurium
Taking a salmonella typhimurium overnight culture bacterial solution at 37 ℃, and mixing the salmonella typhimurium and the culture medium according to a volume ratio of 1:30 transferred to LB liquid medium, then the compound 1, compound 2 and positive control DMSO prepared in example 6 were added separately, and the mixture was cultured by shaking at 37 ℃ and 220rpm in shaking at 37 ℃. Each sample was subjected to three replicates and OD was measured every 2h 600 Values, 12h salmonella growth curves were plotted, and the graph is shown in fig. 5.
As can be seen from FIG. 5, the polycyclic macrocyclic lactams 1 and 2 had little effect on the growth of Salmonella typhimurium at concentrations of 100. Mu.M and 50. Mu.M, respectively.
Example 9: testing the inhibitory Effect of Compound 1 and Compound 2 on the secretion of virulence proteins of the Salmonella type III secretion System in vitro
Testing materials:
salmonella typhimurium UK-1 (χ 8956); compound 1 and Compound 2 prepared in example 6 were dissolved in DMSO respectively to prepare stock solutions at concentrations of 20mM and 4mM, respectively; the positive control Csn-B was synthesized according to the prior art.
The specific test method is as follows:
(1) Inoculating 10 mu L of salmonella stored in glycerinum tubing into 1mL of LB liquid medium for activation, and mixing the activated bacterium liquid according to the volume ratio of 1: transferring 10 of the transfer amount to 1mL of fresh LB liquid culture medium, and performing shake culture at the culture temperature of 37 ℃, the rotation speed of a shaking table of 220rpm and the culture time of 7h;
(2) Taking the culture liquid obtained in the step (1) to mix according to the volume ratio of 1: transferring the transfer amount of 10 into an LB liquid culture medium, wherein the transfer amount is 15 tubes, and the sample culture system of each tube is 1mL; adding the stock solutions of the compound 1 into the tubes 1-6 respectively to make the concentration of the compound 1 be 100, 50, 25, 12.5, 6.25 and 3.125 mu M respectively; adding the stock solutions of the compound 2 into tubes 7-12 respectively to make the concentration of the compound 2 be 100, 20, 4, 0.8, 0.16 and 0.032 mu M respectively; 13-14 tubes are blank controls, and DMSO with the same volume as that of stock solution required by 100 mu M of the compound to be detected is added; 15 tubes are used as positive control, and Csn-B with the final concentration of 100 mu M is added; performing shake culture at 37 deg.C for 7h with shaking table rotation speed of 220 rpm;
(3) Centrifuging the bacterial liquid cultured in the step (2) for 10min at 4 ℃ and 12000rpm, taking 700 mu L of supernatant, adding 150 mu L of trichloroacetic acid solution, mixing the supernatant and the trichloroacetic acid solution gently, and standing the mixture on ice for 30min; centrifuging at 12000rpm at 4 deg.C for 10min, discarding supernatant, inverting, draining, adding 400 μ L precooled acetone, gently shaking, and standing on ice for 10min; continuously centrifuging at 12000rpm for 10min at 4 deg.C, discarding supernatant, inverting, draining, adding 25 μ L1 × loading buffer, dissolving protein by vortex, and heating at 95 deg.C for 5min;
(4) 7.5. Mu.L of the protein sample prepared in step (3) was subjected to 10% SDS-PAGE protein electrophoresis, stained with 0.1% (w/v) Coomassie Brilliant blue R250, destained, and visualized by imaging with a gel imaging system, as shown in FIG. 6.
As seen in FIG. 6, compound 1 and compound 2 have inhibitory activity on the secretion of virulence proteins of the Salmonella type III secretion system and have concentration gradient dependence, compared to the positive control Csn-B (100. Mu.M). The Minimum Inhibitory Concentration (MIC) of Compound 1 was 50. Mu.M, and the MIC of Compound 2 was 20. Mu.M.
In conclusion, the polycyclic macrocyclic lactam compound has no inhibition on the growth of the salmonella, but has stronger inhibitory activity on the secretion of virulence proteins of a salmonella III type secretion system and has concentration gradient dependence. Therefore, the compound has the potential of being used as a novel antibacterial virulence drug.
SEQUENCE LISTING
<110> Shandong university
<120> polycyclic macrocyclic lactam compound and preparation method and application thereof
<160> 6
<170> PatentIn version 3.5
<210> 1
<211> 10005
<212> DNA
<213> Streptomyces sp. S10
<400> 1
atgtcggacc tatgcaaggt cgccacccgc gacaagatcg cgatcatcgg aatcggctgc 60
cgcctgcccg gcggcgcctc ggaccaccgg acgttctggc agaacctgat cgacggcagg 120
gactgcatca ccgcgacgcc cggaagccgg tatgacatcg cgaccctcgc cagccgggac 180
aagaccaagc ccggccgact ggtcggcggg cgcgggggtt acatcgacgg ttttgacgaa 240
ttcgacccgg cgttcttcgg catcagcccc cgcgaggccg cgcacatgga cccgcagcag 300
cgcaagttgc tggaggtggc ctgggaggcg ctggaggacg gcgggcagaa gccggccgag 360
ctggccgggc aggacgtcgg cgtcttcgtc ggcgcgttca cgctggacta caagatcctg 420
caattcgccg acctggggtt cgagacgctg gccgcccaca ccgcgaccgg cacgatgatg 480
acgatggtgt cgaaccgcat ctcgtactgc ttcgacttcc gcggccccag cgtctccctc 540
gacacggcgt gcagttcctc gctggtggcg gtccacctgg cctgccagag cctgagccgt 600
ggcgagagca gcctcgcgct cgccggcggc acgctgctgc acatggcgcc gcagtacacc 660
atcgccgaga ccaagggcgg cttcctctcc cccgagggcc gctcccgcac cttcgacgcg 720
tcggccgacg gttacgtgcg tgccgaaggc gtcggcgtgg tcgccctcaa gcgcctggac 780
gacgccctgc gcgacggcga tccgatccac gcggtggtca tcggcagcgg cgtcaaccag 840
gacggccgta ccaccggcat caccgtgccg aacgccgacg cccaggtcgc cctgatcgaa 900
cgggtctgca ccgaggcggg catcgcgccc ggcagcctgc agtacgtcga ggcccacggc 960
acgtcgaccc cggtcggcga cccgatcgag gcgggcgcgt taggccgggc gctgtcgatc 1020
gggagagaac ccggcgccgc ctgctacgtg ggctcggtca agaccaacat cgggcacacc 1080
gaatcggccg ccggcatcgc cgggttgatc aagacagcgc tctgcctgaa gcaccggaag 1140
atcccacccc acatcaatct cgaccagctc aatcccgcga tcgacctgga cgcgctgccc 1200
taccggatcc cgaccagcac ggtcgactgg ccggagcacg acggacccgc ccgcgccggg 1260
gtcaactcct tcggtttcgg cggcaccaac gcccacgtgc tgctcgaagc ggcaccggcc 1320
cgtgcggagg ccgcgaggaa cacggcagcg gccacgacga gcgcggcagc gggtacggca 1380
gcggccacgg agggcgctga aggcgcggca gcggcttcaa agggcagttc ggcagagggc 1440
gcgacgagca cggcagggac ttcgggcagt gcggcggcgg ccgttgtggg cgcgggggcc 1500
gaggtgggcg tgggggccgg gggctcggcg gcagcggttc cgccttcgta ctccatcctt 1560
ccgctgacca cgcgtgaccc ggcgctgctc cccgaggcgg cggccggcat ccgcaaggag 1620
ctggccgggt ccggccacgc tccggccgcc tcgctgaccg acatcggcta caccctggcc 1680
cgccgtcggc agcacctcga atcgcggctg tcggtcgtct acgactcgcg tacgtcgctc 1740
gaagcggccc tcgacgccta tctgcgcggc gaccagcacc cccatgtgct ggtcgaccag 1800
cggcgcgagg gcgagcagcg gcggctggtc tgggtcttca ccgggatggg gccgcagtgg 1860
tgggccatgg gccggcagtt gttcgagacc gagccggtct accgcgctgc ggtcgaacgc 1920
tgcgaccgcg agatccgtga cctcaccggc tggtcgctgg tggaggagtt gtccgccgac 1980
gaggcggact cgaagatgag cgagacctgg ctggcccagc ccgccaactt cgccgtccag 2040
gtcgggctcg cggccctgtg gcgcagccgc ggcgtccgtc cggacgccgt cgtcggccac 2100
agcaccggcg aggtcgcggc gttctacgaa gcgggcgtct acaccctgcg ggacgcggtc 2160
acggtcgtcg tgcaccgcag ccgcctccag cagaagctcg tggacaccgg cgcgatgctg 2220
gccgtgagtc tgtccgagga ggaggccgag cggcgggtgg cgccgtacgc ggaccgcgtg 2280
tcggtggccg ccgtcaacag cccgacggcg atcaccctcg ccggggacaa ggacgcgctc 2340
gcggagctgg ccctgcaact ccaggcggag gacgtcttcg ccaagttcct caccgtacga 2400
gtgccttacc acagcccccg tatggatccg atcaaggacg agttgctgtc ctcgctcgcc 2460
gcgctggagc cgcgcgccgc gcgggtgccg ctgtatctga cgggagggcc gcaggccgcg 2520
gcccgcggcc gggcggaagg gcccgagctg gacgcggact actggtggcg caacgtccgc 2580
gacagcgtgc gcttccggga cgccgtcgac cgcctcgtcg aggacggcca tggcctcttc 2640
ctggagatcg gcccgcatcc cgtgctgggt cactcgatcg ccgaatgcct gaccgccaag 2700
ggcgccgagg ggcgcagcct gccctcgatc cggcgccagg aggacgagcg cgcgcggttc 2760
accctctccc tcgcggctct ccacaacgcg ggcgtcgaca tcgcctggga ggtactgcac 2820
ccgcggggca ggccggtgcc gctgccccgc tacccctgga agcgggaccg gcactggacg 2880
gagccgaagg cggtcgagca gatccggctc ggcaggcgcg aacacccgct gctgggccgt 2940
cggctggcca cggcggaacc ggcctgggag gcccgactcg acgtcgaggc cctgccctat 3000
ctgctcgacc accgcatcca gggcagtgcg ctgttcccgg cggcgggcta cgtggagatg 3060
gcgacgcagg cggtgcgcgc gatgaccggc ggcggggagg ccgtgatcgc cgacatcgag 3120
ctgcgcaagg cgctgttcct gtcggccggt tcggacggcg ggaacgcccc ggaggagtcc 3180
ggcggtgacc cggccccggc cgccttgggc ggcgacaccg ccaccgtgca gctctccttc 3240
tccgcggaga acgccgcgtt caccgtcgcc acggtgcacg ccgacgactc ccgggagcgg 3300
accgtgcacg cacgcggagt cgtccgtacc gggcaacgcg ccgccggtac ggcccggctc 3360
gacgccggcc cggttaaggc gcgcagcctg cgccgcctcg acggcgccga ctgctatgcc 3420
gccctcagga cgctgggcta ccactacggc ccggcgttcc agggcatcga ggaggtgtgg 3480
atcggccggg acgaggcgct ggcccggatc cgtccgacgg agccgatcgg tgacgacgcc 3540
acccgccacc acatgcaccc ggtcctcctc gacgcctgct tccagaccct gctgaccccg 3600
cagatcgtcg agaccggtga cgacgccggg gacaccgcgg gcggcatccg gctgccgttg 3660
tcgatcgacg aggtgcgcat ggccgccgtg ggcgaccgtg cgctgtgggc gcacgccgtc 3720
gtcacccgcc gggcggacgg tgaactcgtc ggtgacatcg ccgtccacga cgacgacggt 3780
gcgccgctcg gccggatcag cggcttccgc gccgccgaca tcgagaaagc ctccgccgcc 3840
gtcagcctga acaccgtgga ctcctggctg gccgacgtca cctgggtcca cacgccgtac 3900
gcggcggacg tcgacacccc gtacgcggca gacgtcgacg ccccggacac accgggcggc 3960
gacaccgcgt ccgcggcacg caccgacgcc ctccacgcag cggacgccgg cacatcgcgt 4020
acggcggacc cggtcgctcc gtacggggcg gaagccgtcg cgccgtaccc gggagagacc 4080
gtcaccccgt tcccggcaga ggccgtagcc gcgggcggga cggccgcgcc ccgctggctc 4140
gtcctcgccg acggccgcgg cgtcggcgac gcgctcgcgg cgctgatcgc cgggcgcggc 4200
gggcactgcc acctggtacg cccaggagcc gcctaccgcg tcgccgacga cctgcgggag 4260
tcgacggtcc ggccggactc cgccgccgac ctggaccgtc tcctcgccga cctgcgcgcc 4320
gcgggcggcc ggccgtacga ccacgtcgtg cacctgtgga acctcgacct gcccacgttc 4380
gacgcgacgg ccgccgccga cgagctgcgt ggactctccg gtgtcggcgg ctactcgctg 4440
atcgcgctcg cccagacgct gccgtccgcg ctgccgggcg gcaggctgca catcgtcacc 4500
cgcggcgccc aggccgtcgt accgggtgat ccggtcgagc cgctgtccgc tccggcctgg 4560
ggcatcgggc gcgtgctgtg gcagcaggaa ctcaccgccc accgcgggaa gctgatcgat 4620
ctcgatcccg cgtccgcctc gtgcgaggcc gacgccgagg cactgctgcg ggaggtgccg 4680
gccgccggtg ggaccgccga cgacgagatc gcgctgcgcg ccggccaccg ctacaccagc 4740
cgcctcaccc cggtcgccgg ccggctgacc cgtccgctgc cgctgcggct gcgcgccgac 4800
ggcgcctacc tggtgaccgg tgccttcggc gcgctgggcc gggtgctctg ccgcgccctg 4860
gtcgcctggg gcgcacggcg gctgatcctg gtgggccgga cccggctgcc cggccgggag 4920
cactggcgcg agaccgaccc cggctccgcg gccggccgcg ccgtccggtt cgtgcgggag 4980
ctggaggcgc tgggcgccca gcccgtcctc gcgcccctcg acatcagcga cgaggcgagc 5040
ctgacggcct ggctggcgga gtaccggcgg ctcgcgtccg cgccgatccg cggtgtcttc 5100
cacctcgcgg gccaggtccg cgacaccctg ctgcccgaca tggaccggga gaccttcgac 5160
gcggtccacg atcccaaggt cctcggcgcg tacctcctgc accggcatct cggcgcggaa 5220
ccgctcgacc acttcgtgct cttctcctcg atcgcctccg tgctgacgac cgccgggcag 5280
accaactacg cggcgggcaa cgcgttcctc gacgcgctgg cgcaccaccg ccgggcccgc 5340
ggcctgcccg gtctcagcct ggactggggt ccctgggcga ccggcatgat cgaggagctg 5400
gggctcatcg agcactaccg caggaaccgc ggcatgagtt ccctgtcgcc cgaggcgggg 5460
acggccgtgc tggaacgcgt catcgggcag gaccgggccc agctgctcgt cgccaccgtc 5520
gtcgactggc cggtcttcct cgcctggtac gcctccccgc cgccgctggt gagcgagctg 5580
gccgcggccc tgggcggtcc gtccgccgca cagggggaac agagcagctt cctcgacgcg 5640
ttccggggcg ccgatgacgc ggcccgtcgg accctggtgg ccgagcgctt cacggcggtg 5700
gtcgcgggtg tgctgcgggt ggcgaccgac caggtcgagc tcgaccacgc actgggcgga 5760
ctgggcctgg actcgctgct cgcgatggag ctgcgctccc gcgtgcacgc ggaactcggc 5820
ctcgcgctcc cggtcgtcac cctgctcagc agcgccccgg tgggcgaact gatcgaccgg 5880
ctccacgagg gcctggccga gctggtggcg gccggtgcgg acgaggccgc cggcggtgcc 5940
gcggtcgagc tgttccgcga cgagggacgg cacccgctga cccagaacca gaaggcgctg 6000
tggttcctca agcagctcaa ccccgacggt ttcgcctaca acatcggcgg cgcggtcgag 6060
gtgcgcgtgg aactcgaacc ggagctgatg ttcgacgcgt tccgggtgct gatcgagcgc 6120
catcccagcc tgcgcgccaa cttcacgcac gagcaggggc agccggtgca gaaggtcgcc 6180
cccgccgccg aggccgcgct gcgccgggac gtcgccctct tcgacgtgga gggcgtggcg 6240
tgggacgacg tccacgcgat gatcgtgcgc gagtaccgca agccgtacga cctcgaacgc 6300
gacccgctga tccggttgcg cctgttccgg cgcggtcccg accgctgggt gctgatgaag 6360
gccgtccacc acatcatctc cgacgcgatc tctaccttca ccttcatcga ggagctgctc 6420
gcggtctacg aggcgctgcg ccggggccgc gcccccgagc tgccgccggt ctcggcccgc 6480
tacctcgact tcctgaactg gcagaaccag ttcctcgccg gacccgaggc gcgccggatg 6540
ctcgaccact ggaagggccg gctgccggcc gacgtcccgg tgctcggcct gcccaccgac 6600
aagccccgtc ccgcggtgca gacccacaac ggcgcgtccg agttcttcgt gctcgacgcc 6660
gacctcagcg cccgcgtcca cgacgtggcc cgcgagcaca acgtcaccgt gttcatggtg 6720
ctgctcagcg cctactacct gctgctccac cactactccg ggcaggacga catcatcgtc 6780
ggcagcccgg tgacgggccg tacccaggag gagttctcct cggtctacgg ctacttcgtc 6840
aatccgctgc cgctgcacgt cgatctgggg gacggcccgt cggtggagca gttgctcgcc 6900
cgggtccggg atgtcgtgct cggcggcctg gacaaccagg agtacccgtt cgtgctgctg 6960
gtggaggagc tgggcctcca gcacgacccg agccggtccg cggtcttcca agccatgttc 7020
atcctgctca cccacaaggt ggccaccgag aagtacggct accgcctgga gtacatcgaa 7080
ctgcccgagg aggagggcca gttcgacctg acgctgtcgg tgtacgagga cgaggcggac 7140
cggcgtttcc actgcgtctt caagtacaac accgacctgt tcctggccga gacgatgcgg 7200
cggctgtccg ggcactacgt caacgtcctc gacgccctga cccgcgcccc cgccgcgcag 7260
ccggccggcc ggctggaact gctgggcgcc cgtgagcgcc ggcagatcct cggcgactgg 7320
agcggggccg gacgccgggc cgccgagccc ggtgtgccgg tgcacgagct gatcgcccgg 7380
gccgccgccg agcaccccgg ggcgaccgcc gtctgcgtgc ccgccgagga cggcacgacc 7440
gagcgcatga cctacgccgc actcgaccgc cgcagccgcg accgcgcgcg acggctgcgc 7500
gaactgggcg tccgcgacgg cgcggtggtc gccgtctgca tggagaagtc ggccgagctg 7560
gtggtcaccc tgctggcggt cctccgggcg ggcggcgcct atctgccgct cgaccccggc 7620
aacccggccg accggctggc ctacatggcc gagcacgccg gggccgcgcg cgtcgtcgtg 7680
gacggggcgg gcggtgcgcg cttcgccggg cattccggcg tgctcaccct ggcggagctg 7740
tccgacgcgg cgggcgcgcc cggcacggcg gccgccccgc caaaaccggc ggggcaggcg 7800
gaaccggccg ggccgacgga ccagatcgag cccaccgggc aggccaggcc ggtcgcggcc 7860
ggtactgcgg ctgccgcggc cgacgcagcc gatccgaccg acccgaccga cccactcgtc 7920
ggcatggacg gcccggccta cgtcatctac acctccggct ccacgggccg tcccaaggcg 7980
gtgcaggtca gccatcgcaa cctggcgtcc gcctacgccg cctggcgagc ggagtaccgc 8040
ctcgacacgg acgcccgggt ccatctccag atggccggcc cggcgttcga cgtgttcacc 8100
ggtgacctgg tccgcgccct gtgctccggc gggaccctgg tgctggtcgg ccgtgagctg 8160
ctgttcaaca cggcccggct gtacgcgacc atgcgcgccg agcgggtcga ctgcgccgag 8220
ttcgtgccct ccgtcgtgcg cggcctgatg gcccactgcg aacgcgacgg cgcccggctg 8280
gacttcatgc gcctgctgat cgtcggctcg gacacctgga aggtggagga gtacgaccgg 8340
ctgcgcggcc tgaccggacc ggacacccgc gtggtcaact cctacggcct caccgaggcc 8400
accgtggaca gcacctactt cgagggcccg accgacggcc tggaaccgag ccagatggtg 8460
ccgatcggcc ggccgttccc cggtgccgag gtgtacatcc tggacgggca cggcgcaccg 8520
gtgccgccgg gcgtcgcggg cgagctgtgg atcggcggcg ccggggtcgc cctcggttat 8580
ctcgccgatc ccgggcacac cgccgagcgt ttcgtcagcc gcaccctgga ccacggcagc 8640
ggcgcggcac cggtacggct gtaccggacc ggcgacctgg cccgctggga caccggcggc 8700
ggagtccacc tgctcggccg ggccgactca caggtcaagg tcggcggcca ccgggtggag 8760
atcggcgaga tcgagttcca gctcgcggaa tggcccgcgc tggcccaggc ggtcgtcgtc 8820
gtccggccgg accgcaacgg cgagaacacg ctgtgcgcgt acggcgtcgc cgcacccggc 8880
gcgaagctcg actggcggga gctgcgccgg cacctcggcg agcacctgcc gacgtatctg 8940
gtcccggcgg ctttcaccga gctgcccgcg ctgccgctca ccccgaacgg caaggtcgac 9000
gtcaacgcgc tgcccgagcc ccggttcgag accggcgagg acgcccacga gccgcccgtg 9060
acgctctacg agacgcggat ggccgaccac tgggcggcgc tgctcggtct cggggaggtc 9120
ggtctccagc acgacttctt cgaggtcggc ggcagctcca tcaagctgat cgagctgatc 9180
cacgggttgc aggacgagtt cgagatcagc atcccggtca gccagctgtt caaggtcacg 9240
acgctgcacg ggatggcccg gaccgtcgag cacatcatca ccggccggct gccgggcgcc 9300
cagccgttcc tccgcttcaa ccggggggcg ggtcccgccg tgttctgctt cccgcccgcg 9360
ggcgggcacg gcctggtcta ccggcggttc gccgagcagc tgccggagta cgaactcgtg 9420
gcgttcaact acgtcgccga ggacgacaag gtcgcccggt acgccgatct gatcgccgcg 9480
caccagcccg aggggccctg cgcgctgctc ggctactccc tcggcgggaa cctcgccttc 9540
gaggtggcca aggaactcga acggcgcggc cgtgaggtcg ccgacgtcgt catcgtcgac 9600
tcgtaccgca tcgatgccgc cttcaccccg ggcgccgagc acatcgaggc gttcgagcgg 9660
gagctgcgcg agcacctgca caagcacacc ggctccgaga ccctcgcgca ggagaccctc 9720
gaccaggcca gggactacat cgccttctgc ggccgtactc ccaacctcgg cacggtcggc 9780
gcggccgtca ccgtcgtctc cgacgagcag aaggtggcct tctacgccgc gggcgagcgc 9840
gggacctggc acggcacctc gaccgtgcgc accgaggtgc tgcgcggcgc cggcgtccac 9900
gcggacatgc tcgacccggg gtgcatcgag cacaacgccc ggctggtgcg cggcgtcctc 9960
acgcacaccg ccgtgatcga aggggcggcc ccgcatgcgg cgtag 10005
<210> 2
<211> 1665
<212> DNA
<213> Streptomyces sp. S10
<400> 2
atgcggcgta gtaacagggt gcagtggagc gaacgcgagc gtgcccccgg ggccaagccg 60
cgcgtcatca tcgtcggagc gggcctgggc gggctctccg ccggctgcta cgggcagatg 120
agcggcatgg agacccgtgt cttcgagaag cacgtgctgc cgggcggctg ctgcacggcc 180
tggtcccggg acggctacgt cttcgactac tgcatcgaat ggctgaccgg caccgccccg 240
ggcaacgagg cccatcaggt ctggcgcgag ctgggggccc tggacgggaa gaccatccgc 300
aacttcgagg tgttcaacac ggtcgtcgac gacgacggcc ggtcggtggt cttctacaac 360
gaccccgacc ggctggagcg gcacctgctg cggctctcgc cggcggacgc gccgctgatc 420
cggtcgttct gccgtgacct gcggcggttc accgacatcg acatcttccc gttcctgaag 480
ccggccccgc tgctgacgct gcgggagaag gccagggcgc tgcggaagat cctgccgctg 540
ctgaacctgt tccggcgcac cgccgggacc tccatggagt ccttcgccgc gcgcttcgag 600
gatccgctgc tgcgccgggc gctgccgttc gtcttcttcc aggaccacga ggtcttccca 660
ctgctgccgt acctgttcaa catggcgggg gcccaccagt ccaacgcggg cttcccgcag 720
ggcggttcgc tggggctggc ccggtcgatc gaggagcgct acacctcgct cggcggccgg 780
atcgactacc gcgcccgggt ggagcagatc ctggtcgagg acggccgggc gatcggcgtg 840
gaactgcgcg gcggcgagcg gcactacgcg gaccacgtgg tggcggcctg cgacggcgcc 900
accaccctgg accggttgct gaagggacgc tactccagcc cgcggaccga ccggctgttc 960
cagtcggtcc tcggcacccc gaagctggtc tacccggggg tggtgtcggt gttcgtcggg 1020
ttcgccgggg acgtggcgcc ggacgccccg cacagcgcga cctatctgct ctccgccgcc 1080
gacagcgccc ggctgcccgg cgtgctccag gacagtctgg tggtgcagtt gcgctcccgg 1140
ttctcggacg ggctggcacc gcccggcaag tcggtgatcc actgctccta cttcagcgac 1200
tacagctcct ggaaggaact gcgccgcacc gaccgccgcg cctaccgggc gcgcaagcag 1260
gaggccggcc ggttcgtgcg ggagttcctg gagcgccacc atccggggat cgccgcgcgc 1320
atcgaggtgg tcgacgtcgc cacgcccgcg accaccgagc gctacaccgg caatctgcac 1380
ggctccatcc tcgcctggaa gtcctacacc gaagccgacg gcctgatcca gcacctgatc 1440
gagaaggacc ggctgcggct gccggggctc gacgggctct cgctggcggg tcagtggttc 1500
accggcggcg ggctgatccg ggtggcggcc ggcggccggt tcgtggccca gtacctctgc 1560
gaggagctgg gcctcgagtt ccgggcgtgg gagagcacgg ccggtgagac gtggcatccc 1620
gggaagctgg gccacctgcc ccagctcgac aagagcatga ggtga 1665
<210> 3
<211> 1734
<212> DNA
<213> Streptomyces sp. S10
<400> 3
atgcctcgca agccccgcga gcgccagaca atgatcatca tcggggccgg tctcggcggg 60
ctgtccaccg gctgctacgc gcagatgaac ggctaccgga cccggatctt cgagatgcac 120
gagatcccgg gcggctgctg cacggcctgg gaccgtggcg acttcacctt cgactgctgc 180
gtcagctggc tgctcggcaa cgggcccggc aacgagatgc accagatctg gctggagctg 240
ggcgcgctcc agggcaagca gatgcggcac ttcgacgtct tcaacgtggt gcgcgggcgg 300
gacggccggt cggtctactt ctattccgac ccggaccggc tcgaagccca tctgctggag 360
atctccccgt ccgacgccag gctgatccga agtttctgct cggggctgcg gaagttccgc 420
aagtgccttg ccgcgtatcc cttcctcaaa ccggtgggac tgatgggccg cgccgaacgc 480
tggcgcatgc tcgcgtcgtt cgtcccctat ttcaatgtca tccgcaagtc gatcagcgtc 540
ctgatgacgg actattccgc gaagttcagg gatccgctgc tgcgcgaggc gttcaatttc 600
atcctctacg agaagcattc cgcttttccg gtgctgccgt tctatttcca gctgtccgcg 660
cacgccaatc tctcggccgg ggtgccggag ggcggctcac tggggctcgc gacctcgatc 720
gagcagcgct atctgcggct cggcggcgag gtcagctaca acacgaaggt cgaggagatc 780
ctcgtcgagg acgaccgggc ggtgggggta cggctcagcg acgggcggga gttccgcgcg 840
gacatcgtgg tctcggcctg cgacgggcac gccaccacga tgaagctcct gaagggccgt 900
tacctccccg aggagtaccg gcggctgtac acctcggtca tcgacgagcc gggcatggtc 960
ttccccggat acgtcaccct cttcctcggg ctgcggcgcc ccttccccga gggcgccccc 1020
tgcaccacgt acctgctgac cgaggaggag gccacccggc tggtcggcat ccgccatccg 1080
agcatcaacg tccagttccg cagcctgcac tacccggagc tgtcgcccga gcggtcgacc 1140
gtcgtctacg ccacctactt cagcgacgtc ggtccctggc gcgcgctgag cgacggcccg 1200
gagcagcgca cccgcagccg gggcggaacg gagctgcaca ccctgccggt gcgccgcggg 1260
cgcccgtact acgaggctaa gcaccaggtg cgcgacatgc tgctgggctt cctcgaccgg 1320
cggttccccg gcctgacgga cagcgtcgcg gtgcgggacg tgtcgacccc gctcacccag 1380
gtccgttaca ccgggaacta cgacgggacc gtcctcggct ggcagccgtt cgtggaaagc 1440
ggcgagacga tggagaaggt cgtcaagaag tacgggccgg ccctgcccgg cctcgcgaac 1500
ttctacctct ccggggtctg ggccaccacc ggcggcctca tccgcgccgc ggccgccggc 1560
cggcacgtca tgcagttcgt ctgccgcgac gacggcaggg cgttcaccgc acacatcgac 1620
gcgtcggggc cgctcccgac ccatgtcgtc atccccgtag gacccgatgg gaaggatgga 1680
gaccccgatg agcgaacgac cggcgccgct gccgtatccg ttcacgtccg ctga 1734
<210> 4
<211> 1056
<212> DNA
<213> Lysobacter enzymogenes C3
<400> 4
atgaagaccg aacgttgggt ggtacgcgaa cacgtcgagg gcgtgcccga tgccgcgcgc 60
atctacgaaa aagtcgagac cgaactgaac acgcgcctgg gcgaggagca gatgctgctc 120
aagaccctgt acgtgtcggt cgatccctac ctgcaaggca tctgcctgga cacgccgatc 180
ggcgaccaca tgggcgccga ctcgatcatg caggtgctcg atgccggccc gaacgcgccg 240
ttccggccgg gcgacctggt gcagggcttc ggcggctggc gcacgcacct ggtcagcgac 300
ggcaagccca agctgtggca gaccggcacc ttcccgatgg tgttcccggc ctatcgcaag 360
ctcgacctgc gccactacga cgacgccctg ccgctgtcga ccgcgctcgg cgtgatgggc 420
ggccccggca tgaccgcctg gggcacgatg accaaattca tgcaggtgcg tcccggcgac 480
accgtcgtgg tcagcggcgc ctcgggcatg atcggcaccc tggttgggca gatggccaag 540
cgcgccggcg cgcgcgtggt cggcaccgcc ggctcggccg gaaaggcccg ctacctgagc 600
cagctcggct tcgacgcggt gatcgactac aagctcgccg acgacgccga caagatgcgc 660
gaagcgctgc gcgaggccgc gcccgacggc gtggacaagt acttcgacag catcggcggc 720
agcgtcaccg acgcggtgtt ctcgatgctc aacgtcggca gccaggtcgc ggtgtgctgg 780
caatgggcga cccaggtcca gcgcgactac cacggtccgc gcctgctgcc ctacatcatg 840
ttcccgcgcg cgaccatccg cggcatcttc tcgctggagt ggttcaccga gcagaactgg 900
agcgcgctgc acgaggaact cggcgggctg gtgcggcggc aagagctggt cgcgcacgaa 960
accgtgcagg acgggttcga gcatattccc gccgcatacc agacgctgtt ctcggccagt 1020
gaaagcaacc gcggcaaggt gctggtgcgg gtgtga 1056
<210> 5
<211> 1191
<212> DNA
<213> Streptomyces griseus IFO 13350
<400> 5
atgaccacca ccgacccgac ccgcccggcc ccggtcccga tgcaccgcct gttcttcgag 60
gagccgggcc cgccgcgccc ggccgagctg ccgggcggcg acccggcctg gttggtgtcc 120
cgctacgccg acgtccgcca ggtcctgtcc gacccgcgct tcggccgcgc ccgcctgtac 180
gccccggagg ccccggccct gtccggcgtc ccggacctgg tcaacaaccc ggacctgatg 240
ttcaaccagg acggctccga ccacctgcgc ctgcgccgca ccctgcgccg cgccttcacc 300
ccgcgcgccg tcgcccgctg gcgcccgtgg atcgccgcca ccgtcgaggg catcctggac 360
cgcctggagt cccgcccgca gccggccgac gtcgtcgccg agttcgccct gccgctgccg 420
gtcgccgtca tctcccgcct gatgggcctg gacgagtccg tctgggaccg catgcgctac 480
tggtccgagc acgccttctc cgacggcacc cacgagcgcg agcaggtcgc cgccgccctg 540
aaggagttct ccgccttcgg cgcccacctg ctggccgagc gccgctccac cccgggcgag 600
gacctcgtgt ccggcctggt caccgccgcc gacgaggagg gcggcgtccc ggaggcccag 660
ctggtgtccc tggtctgcgg cctggtcgtc ggcggccacg actccaccat gaccatgctg 720
ggcaacgccc tgctgtacct gctgggcgag cgccgcgaga catggccgcg cctgggcgcc 780
gacgaggagg ccgccggcct gctggtcgag cgcctggtcc acctggtccc gctgggcgac 840
gaccgcggct ccacccgcca cgccgccgag gacgtcgaag tctccggcgt ccgcatcccg 900
gccggcgcca tcgtcatcgc cgactgcggc atggccaacc gcgacccgga ggtcttcccg 960
ccggccaccc tgtacgacct gttcgccccg ctggaggccc cgaccctgtc cttcggcgcc 1020
ggcccgcact actgcctggg cgcctggctg gcccgcaccg agctgcaact ggccctgcac 1080
cgcctggccg cccgcttccc ggagctgcgc ctggccgacc cggtcgacgc cgtcgtctgg 1140
cgcaccggca ccacctcccg ctccccgcgc cgcctgggcg tccgctggtg a 1191
<210> 6
<211> 1200
<212> DNA
<213> Streptomyces albus J1074
<400> 6
atgtccgccg caacacccgc ccccgccgga gccgttccgc cgctcgcccc gctccaccgc 60
cgggcgcccg ccgagccggg accgccccgg ccgtgcaccc tgcccgacgg ttcccccggc 120
tggctggtcg accgctacgc cgacgtacgg caggtgctca gcgacagccg gttcggccgc 180
gccgggctct acctccagga cggcccctcc cgctcccagg cggccggact ggtggacgac 240
ccggagctga tgttcaacca ggacggcgtc gagcacctgc ggctgcgccg caccctgcgc 300
cgggccttca ccccgagggc cgtcgcccgg tggcgcccct ggatcgcctc gatcgtcgac 360
cagctcctgg acgacctgtc ggcgcggagc ggaccggtgg acgccgtcgc cgagttcacc 420
ctgccgctgc cggtcgccgt gatcagccgc ctgatgggcc tcgacgcctc ggtgcgtggc 480
cggatgcgcc actggagcga acacgccttc tccgacggca cccggcccaa ggacgaggtg 540
gacgcggcgc tcgcggagtt caccgccttc ggcgcccgac tgctcgccca gcggcgccgg 600
gcccccggcg acgacctggt cagcagcctg gtgcgggccg ccgacgccga gggcggcatc 660
cccgaggacc gtctcgtcag cctggtctgc ggcctggtgg ccggcgggca cgacagcacc 720
atgacgatgc tcggcaactc cctgctctac ctgctcgcgg aacggcccga ggagtggccc 780
cggctggccg acgagccctc ggcggagctg gccgccgccc gcctgatcca cctgatcccg 840
ctcggcgacg acccgggcag cacccgctgc gccaccgagg acgccgaggt cgggggcgtc 900
ctcatcccgg ccggcgcggt ggtcctcgcc gactccacca ccgccaaccg cgacccgtcg 960
gtcttcccgg ccgcgcagac cgaggccctc ttcaccccgc tgccggcgcc caccctcgcc 1020
ttcggcgcag ggccccacta ctgcctgggc acctggctcg cccggctcga actccacctg 1080
gccctgcacc ggctggcggt ccgcttcccc gggctgcggc tcgcggaacc ggagaagccg 1140
gtccgctggc gcccggccgg cacctcacgc agccccgaac ggctcccggt cacctggtga 1200

Claims (6)

1. The polycyclic macrocyclic lactam compound is characterized by having a structural formula shown as the following formula:
Figure DEST_PATH_IMAGE001
the preparation method of the polycyclic macrocyclic lactam compound comprises the following steps:
a. engineering bacteria S001-cbm-OX4-sshg_05717Inoculating on YMG solid agar medium, and performing extended culture at 25-35 deg.C for 8-15 days;
b. YMG solid agar medium and engineering bacteria S001-cbm-OX4-sshg_05717Cutting the thalli into blocks, soaking and extracting 2~4 times by using ethyl acetate-methanol-glacial acetic acid overnight, mixing leaching liquor, respectively mixing a water phase and an organic phase of the leaching liquor, concentrating under reduced pressure to 200-400 mL, respectively extracting 2~4 times by using ethyl acetate with the same volume, mixing extracted ethyl acetate phases, and concentrating under reduced pressure to be dry to obtain an ethyl acetate extract, wherein the volume ratio of the ethyl acetate to the methanol-glacial acetic acid is 80;
c. extracting the ethyl acetate extract by using petroleum ether and methanol with equal volume to obtain a methanol phase and a petroleum ether phase, separating out a light yellow precipitate from the methanol phase, washing the light yellow precipitate for 2~4 times by using methanol-dichloromethane with the volume ratio of 2:1, and then carrying out chromatography separation by using a sephadex column to obtain a component 1, wherein the component 1 is prepared by using HPLC to obtain the polycyclic macrocyclic lactam compound shown in the formula;
the engineering bacterium S001-cbm-OX4-sshg_05717Contains polyketide-nonribosomal peptide synthase gene responsible for synthesis of PoTeMs polyene skeletoncbmAThe nucleotide sequence is shown as SEQ ID NO. 1; flavin-dependent oxidoreductase genes responsible for the synthesis of the intermediate five-membered ring of a polycyclic systemcbmBThe nucleotide sequence is shown as SEQ ID NO. 2; flavin-dependent oxidoreductase genes responsible for the synthesis of five-membered rings outside the polycyclic systemcbmCThe nucleotide sequence is shown as SEQ ID NO. 3; NADPH-dependent oxidoreductase genes responsible for the synthesis of six-membered rings inside polycyclic systemsOX4The nucleotide sequence is shown as SEQ ID NO. 4; cytochrome P450 enzyme genes responsible for post-oxidative modificationsshg_05717The nucleotide sequence is shown as SEQ ID NO. 6;
the engineering bacterium S001-cbm-OX4-sshg_05717The construction method comprises the following steps:
(1) By StreptomycesStreptomyces Performing PCR amplification by using genome DNA of sp, S10 as template, and introducing the obtained sequence at both endsNdeI andSpei flavin-dependent oxidoreductase gene of the enzyme sitecbmBAnd flavin-dependent oxidoreductase genecbmCA gene fragment; by lysobacter enzymogenesLysobacter enzymogenesPCR amplification is carried out by using genome DNA of C3 as a template, and two ends of the obtained sequence are respectively introducedNdeI andSpei NADPH-dependent oxidoreductase of the cleavage siteOX4A gene fragment; by streptomyceteStreptomycesalbusJ1074 genome DNA is used as a template for PCR amplification, and two ends of the obtained sequence are respectively introducedNdeI andSpecytochrome P450 enzyme gene of I enzyme cutting sitesshg_05717A gene fragment; the four PCR products were subjected toNdeI andSpei after double digestion, obtainingcbmB-NdeI/SpeI、cbmC-NdeI/SpeI、OX4-NdeI/SpeI andsshg_ 05717-NdeI/Spea fragment I;cbmB-NdeI/SpeI、cbmC-NdeI/SpeI、OX4-NdeI/Spei andsshg_05717- NdeI/Spei is respectively linked with the vector fragment pUC-kasOp*/ermEp*-NdeI/SpeI is connected by ligase, the connection products are transformed into Escherichia coli DH5 alpha competent cells respectively, experienceObtaining plasmid pUC-cbmB、pUC-cbmC、pUC-OX4And pUC-sshg_05717
(2) Plasmid pUC-cbmBAnd pUC-OX4Respectively pass throughMfeI andSpei obtained after double digestioncbmB-MfeI/SpeI andOX4- MfeI/Spea fragment I; plasmid pUC-cbmCAnd pUC-sshg_05717Respectively pass throughXbaI andPsti obtained after double digestioncbmC-XbaI/PstI andsshg_05717-XbaI/Psta fragment I; will be provided withcbmB-MfeI/SpeI、cbmC-XbaI/PstI and vector fragment pSET5035-MfeI/PstI is connected by ligase to obtain a plasmid pSET5035-cbmB-C OX4-MfeI/SpeI、sshg_ 05717-XbaI/PstI and vector fragment pSET5035-MfeI/PstI is connected by ligase to obtain a plasmid pSET5035-OX4-sshg_05717
(3) Plasmid pUC-cbmAWarp beamMfeI andSpei obtained after double digestioncbmA-MfeI/SpeI; plasmid pSET5035-cbmB-CWarp beamXbaI andPsti obtained after double digestioncbmB-C-XbaI/PstA fragment I;cbmA-MfeI/SpeI、cbmB-C-XbaI/Psti and vector fragment pSET5035-MfeI/PstI is connected by ligase to obtain a plasmid pSET5035-cbmA-B-C
(4) Plasmid pSET5035-cbmA-B-CWarp beamMfeI andSpei obtained after double digestioncbmA-B-C-MfeI/SpeA fragment I; plasmid pSET5035-OX4-sshg_05717Warp beamXbaI andPsti obtained after double digestionOX4-sshg_05717-XbaI/PstA fragment I; cbmA-B-C-MfeI/SpeI、OX4-sshg_05717-XbaI/Psti and vector fragment pSET5035-MfeI/PstI is connected by ligase to obtain an expression vector pSET5035-cbm-OX4-sshg_05717
(5) The expression vector pSET5035 obtained in the step (4)cbm-OX4-sshg_05717Electrically transformed into competent Escherichia coli S17-1 cell, and transferred to expression vector via donor Escherichia coli S17-1Streptomyces sp. S001, obtaining the engineering bacteria S001-cbm-OX4-sshg_05717
2. The polycyclic macrocyclic lactam compound of claim 1, wherein in step (1), said PCR amplification primer sequence is as follows:
NdeI-cbmB-F: 5’-cggacatatgcggcgtagtaacagggtg-3’
SpeI-cbmB-R: 5’-attactagttcacctcatgctcttgtcg-3’
NdeI-cbmC-F: 5’-cggacatatgcctcgcaagccccg-3’
SpeI-cbmC-R: 5’-attactagttcagcggacgtgaacgg-3’
NdeI-OX4-F: 5’-aggcggacatatgaagaccgaacgttgggtgg-3’
SpeI-OX4-R: 5’-attactagttcacacccgcaccagcacct-3’
NdeI-sshg_05717-F: 5’-cggacatatgtccgccgcaacacccgcc-3’
SpeI-sshg_05717-R: 5’-attactagtcaccaggtgaccgggagcc-3’
PCR amplification conditions: pre-denaturation at 95 deg.C for 5min; denaturation at 95 ℃ for 30sec, annealing at 65 ℃ for 30sec, elongation at 72 ℃ for 2min,30 cycles; final extension, 5min at 72 ℃.
3. The polycyclic macrolactam compound of claim 1, wherein in step (3), said plasmid pUC-cbmAThe preparation method comprises the following steps:
to contain polyketide-nonribosomal peptide synthase genecbmAPerforming PCR amplification by using fosmid XIV-12H as a template, and respectively introducing two ends of the obtained sequenceNdeI andSpei part of the cleavage sitecbmAA fragment; the obtained PCR product is subjected toNdeI andSpei after double digestion, obtainingcbmA-part1-NdeI/SpeA fragment of the I-form of the polypeptide,cbmA-part1-NdeI/Spei fragment and vector fragment pUC-ermEp*- NdeI/SpeI is connected by ligase, the connecting product is transformed into escherichia coli DH5 alpha competent cells, and plasmid pUC-cbmAPart1, this plasmidPstI andSphi is obtained after double digestioncbmA-part1-PstI/SphA fragment I; fosmid XIV-12H viaPstI andSphi is obtained after double digestioncbmA-part2-PstI/SphA fragment of the I-form of the polypeptide,cbmA-part1- PstI/Sphi fragment andcbmA-part2-PstI/Sphthe I fragment is connected by ligase, the connection products are respectively transformed into escherichia coli DH5 alpha competent cells, and plasmids pUC-cbmA
Wherein, the PCR amplification primer sequence is as follows:
NdeI-cbmA-LF: 5’-cggacatatgtcggacctatgcaaggtc-3’
SpeI-cbmA-LR: 5’-attactagtctacgccgcatgcgagattgatgtggggtggga-3’
PCR amplification conditions: pre-denaturation at 95 deg.C for 5min; denaturation at 95 ℃ for 30sec, annealing at 65 ℃ for 30sec, elongation at 72 ℃ for 2min,30 cycles; final extension, 5min at 72 ℃.
4. The polycyclic macrocyclic lactam compound of claim 1, wherein in step a, the scale-up culture is 8-10L, and the culture conditions are 30 ℃ for 12 days;
the formula of the YMG solid agar culture medium is as follows: yeast extract 4g, malt extract 10g, glucose 4g,10M NaOH to adjust pH to 7.2-7.4, pure water to 1L,2% agar, and autoclaving at 115 deg.C for 30min.
5. Use of a polycyclic macrocyclic lactam compound of claim 1 in the preparation of a medicament for the secretion of a virulence protein of a gram-negative bacterium.
6. An anti-gram-negative bacterial virulence protein secretion drug comprising a polycyclic macrocyclic lactam compound of claim 1 and one or more pharmaceutically acceptable carriers or excipients.
CN202110450117.XA 2021-04-25 2021-04-25 Polycyclic macrocyclic lactam compound and preparation method and application thereof Active CN113121545B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110450117.XA CN113121545B (en) 2021-04-25 2021-04-25 Polycyclic macrocyclic lactam compound and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110450117.XA CN113121545B (en) 2021-04-25 2021-04-25 Polycyclic macrocyclic lactam compound and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN113121545A CN113121545A (en) 2021-07-16
CN113121545B true CN113121545B (en) 2022-11-11

Family

ID=76779832

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110450117.XA Active CN113121545B (en) 2021-04-25 2021-04-25 Polycyclic macrocyclic lactam compound and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN113121545B (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105961411B (en) * 2016-05-03 2018-05-11 江苏省农业科学院 A kind of biological bactericide and its production method for preventing Fungus of Pear Canker Disease
CN106008531B (en) * 2016-05-30 2019-01-11 上海交通大学 The anti-pancreatic cancer purposes of polycyclic condensed macrolactams compound
CN108623607B (en) * 2017-03-24 2021-04-27 中国海洋大学 5,5, 6-polycyclic tetramic acid-containing macrocyclic lactam compound and preparation method and application thereof
CN106946892B (en) * 2017-05-05 2019-02-01 江苏省农业科学院 A method of rapidly and efficiently extracting active antibacterial substance HSAF in fermentation liquid
CN107119088A (en) * 2017-05-05 2017-09-01 江苏省农业科学院 A kind of molten bacillus OH11 production active antibacterial materials HSAF of response phase method optimization producing enzyme method
CN107568235B (en) * 2017-10-26 2020-03-31 江苏省农业科学院 Bactericidal composition containing difenoconazole and biological antibacterial substance HSAF and application thereof
CN110387389B (en) * 2018-04-19 2022-11-08 江苏省农业科学院 Method for improving fermentation yield of antifungal active substance HSAF
CN109666606B (en) * 2018-12-28 2021-11-16 中国科学院沈阳应用生态研究所 Actinomyces variegata and preparation and application of antimicrobial and antitumor active substances thereof
CN111253408B (en) * 2020-02-11 2021-03-19 中国科学院南海海洋研究所 Antibiotic pactamide G, preparation method thereof and application thereof in preparation of antibacterial drugs
CN112680394B (en) * 2021-01-14 2022-10-04 中国海洋大学 Method for improving biosynthesis amount of natural product

Also Published As

Publication number Publication date
CN113121545A (en) 2021-07-16

Similar Documents

Publication Publication Date Title
DK2271666T3 (en) NRPS-PKS GROUP AND ITS MANIPULATION AND APPLICABILITY
CN110218244B (en) Compound ilamycin F and application thereof
CN108441459B (en) Recombinant streptomyces tuberculatus capable of producing amphotericin B at high yield and application thereof
KR20110118545A (en) New kanamycin compound, kanamycin-producing streptomyces sp. and kanamycin producing method
CN101275141A (en) Biological synthesis gene cluster for Azintamide
CN108753674B (en) Gene cluster for regulating and controlling milbemycin synthesis, recombinant streptomycete, and preparation method and application thereof
JP5422387B2 (en) Method for producing non-natural antibiotics
CN107881205B (en) Function and application of oxidase in bicyclomycin biosynthesis
CN108048472B (en) Engineering strain for high-efficiency heterologous expression of Disorazole Z, gene cluster for constructing strain and application of gene cluster
CN107540682B (en) Streptovaricin derivative and its preparation method and application
CN111253408B (en) Antibiotic pactamide G, preparation method thereof and application thereof in preparation of antibacterial drugs
CN113121545B (en) Polycyclic macrocyclic lactam compound and preparation method and application thereof
CN110563783B (en) High-efficiency low-toxicity tetramycin B derivative and directed high-yield metabolic engineering method thereof
CN110857447B (en) Method for increasing yield of milbemycins A3/A4 or derivatives thereof
CN110305881B (en) Biosynthetic gene cluster of polyketide neoenterocins and application thereof
CN111170975B (en) Antibiotic lobophorin, preparation method and application thereof
CN104263738A (en) Biosynthesis gene cluster of FAS II inhibitor ABX
CN108587991B (en) Bacterial strain for highly producing cyclic peptide compounds
CN110343650B (en) Recombinant streptomyces tuberculatus for producing amphotericin B and application thereof
CN112409372A (en) Rubicin analogue, preparation method and application thereof
CN110551739A (en) Pyrazolomycin biosynthesis gene cluster, recombinant bacterium and application thereof
CN107164394B (en) Biosynthetic gene cluster of atypical keratinocyte compound nenestatin A and application thereof
La et al. Effects of glycerol and shikimic acid on rapamycin production in Streptomyces rapamycinicus
CN110129244B (en) Streptomyces chassis strain, construction method thereof and application thereof in heterologous expression research
CN112342203B (en) Application of ribosome sigma factor, mutant thereof and protein obtained by encoding to increase yield of lipstatin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant